Skip to main content
OpenTrials
Completed

NCT Number: NCT02629497

Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus

This study investigates the potential protective effects of fatty acid supplementation through inhibition of platelet activation. fatty acids (omega-3 and omega-6) will be evaluated for protection from agonist-mediated platelet activation in platelets from type 2 diabetics and healthy controls. Post-menopausal women with type 2 diabetes mellitus and healthy post-menopausal women will be treated with omega-3 and omega-6 fatty acid supplements to determine protection from platelet activation and thrombosis in this high risk population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

University of Michigan

Ann Arbor, Michigan, 48109, United States

About this study

Essential fatty acids such as omega-3 and omega-6 have been shown to play important roles in regulating platelet activation, but the underlying mechanisms have not been fully elucidated as well as their true protection from thrombosis.

12-lipoxygenase oxidized fatty acids are known to play both a pro- and anti-thrombotic effect on platelets depending on the fatty acid. oxidation of arachidonic acid by 12-lipoxygenase resuts in a pro-thrombotic bioactive lipid whereas oxidation of the omega-6 fatty acid DGLA found in plant oil results in formation of a potent anti-thrombotic bioactive lipid. Determining the extent of protection from this and other bioactive lipids produced through oxygenase activity will allow for a better understanding of which fatty acid supplementation may best protect from thrombosis.

Essential fatty acids such as omega-3 (DHA/EPA) and omega-6 (DGLA) appear to be protective. However the underlying mechanism for this potential protection is not well understood. Identifying the mechanism by which these supplements protect from platelet activation may identify new approaches to preventing thrombotic events in this high risk population.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects and T2DM patients
  • Postmenopausal women with T2DM
  • All races and ethnicities
  • T2DM patients taking 1st line diabetic treatment (i.e. Metformin)

Exclusion criteria

  • Fish and plant oil supplements 2 months prior to enrollment
  • NSAIDS and aspirin 1 week prior to enrollment
  • Cardiovascular event within 6 months prior to enrollment
  • Other anti-platelet treatment including PDE and P2Y12 inhibitors

Treatment and study plan

Primrose oil

Dietary Supplement

T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.

Fish Oil

Dietary Supplement

T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.

Other names: DHA/EPA

Primary outcomes

  1. platelet reactivity

    Time frame: through study completion, an average of 1 year

    decreased platelet activity ex vivo translating to protection from clot formation in vivo

Secondary outcomes

  1. fatty acid incorporation

    Time frame: through study completion, an average of 1 year

    measure altered levels of essential fatty acids in blood and platelets following treatment

  2. Oxylipin production

    Time frame: through study completion, an average of 1 year

    determine the oxylipin products formed following each intervention

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

Registry information

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Dec 14, 2015
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.